Advertisement

Index by author

November 01, 1996; Volume 50,Issue 5

A

  1. Akil, H

    1. Mutagenesis of residues adjacent to transmembrane prolines alters D1 dopamine receptor binding and signal transduction.
      W Cho, L P Taylor and H Akil
      Molecular Pharmacology November 1996, 50 (5) 1338-1345;

  2. Andrade, R

    1. 5-Hydroxytryptamine4 receptors reduce afterhyperpolarization in hippocampus by inhibiting calcium-induced calcium release.
      G E Torres, C L Arfken and R Andrade
      Molecular Pharmacology November 1996, 50 (5) 1316-1322;

  3. Aoki, Y

    1. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
      M Minami, T Nakagawa, T Seki, T Onogi, Y Aoki, Y Katao, S Katsumata and M Satoh
      Molecular Pharmacology November 1996, 50 (5) 1413-1422;

  4. Arfken, C L

    1. 5-Hydroxytryptamine4 receptors reduce afterhyperpolarization in hippocampus by inhibiting calcium-induced calcium release.
      G E Torres, C L Arfken and R Andrade
      Molecular Pharmacology November 1996, 50 (5) 1316-1322;

  5. Arion, D

    1. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
      D Arion, R S Fletcher, G Borkow, M J Camarasa, J Balzarini, G I Dmitrienko and M A Parniak
      Molecular Pharmacology November 1996, 50 (5) 1057-1064;

  6. Asai, T

    1. Cyclic AMP-independent inhibition of cardiac calcium current by forskolin.
      T Asai, S Pelzer and T F McDonald
      Molecular Pharmacology November 1996, 50 (5) 1262-1272;

B

  1. Baker, I

    1. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system.
      J M Masserano, L Gong, H Kulaga, I Baker and R J Wyatt
      Molecular Pharmacology November 1996, 50 (5) 1309-1315;

  2. Baldwin, H A

    1. Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury.
      N Tindberg, H A Baldwin, A J Cross and M Ingelman-Sundberg
      Molecular Pharmacology November 1996, 50 (5) 1065-1072;

  3. Balzarini, J

    1. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
      D Arion, R S Fletcher, G Borkow, M J Camarasa, J Balzarini, G I Dmitrienko and M A Parniak
      Molecular Pharmacology November 1996, 50 (5) 1057-1064;
    2. Antiretrovirus specificity and intracellular metabolism of 2',3' -didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324.
      J Balzarini, H Egberink, K Hartmann, D Cahard, T Vahlenkamp, H Thormar, E De Clercq and C McGuigan
      Molecular Pharmacology November 1996, 50 (5) 1207-1213;
    3. Evidence for distinction of the differentiation-inducing activities and cytostatic properties of 9-(2-phosphonylmethoxyethyl)adenine and a variety of differentiation-inducing agents in human erythroleukemia K562 cells.
      S Hatse, E De Clercq and J Balzarini
      Molecular Pharmacology November 1996, 50 (5) 1231-1242;

  4. Bartholdi, M F

    1. Bombesin-like peptide receptor subtypes promote mitogenesis, which requires persistent receptor signaling.
      R I Feldman, M F Bartholdi and J M Wu
      Molecular Pharmacology November 1996, 50 (5) 1346-1354;

  5. Bédard, P J

    1. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
      M Morissette, M Goulet, F Calon, P Falardeau, P J Blanchet, P J Bédard and T Di Paolo
      Molecular Pharmacology November 1996, 50 (5) 1073-1079;

  6. Benke, D

    1. Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2.
      F Knoflach, D Benke, Y Wang, L Scheurer, H Lüddens, B J Hamilton, D B Carter, H Mohler and J A Benson
      Molecular Pharmacology November 1996, 50 (5) 1253-1261;

  7. Benson, J A

    1. Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2.
      F Knoflach, D Benke, Y Wang, L Scheurer, H Lüddens, B J Hamilton, D B Carter, H Mohler and J A Benson
      Molecular Pharmacology November 1996, 50 (5) 1253-1261;

  8. Betz, H

    1. Novel antagonists of the inhibitory glycine receptor derived from quinolinic acid compounds.
      V Schmieden, S Jezequel and H Betz
      Molecular Pharmacology November 1996, 50 (5) 1200-1206;

  9. Biancalana, S

    1. Discovery of high affinity bombesin receptor subtype 3 agonists.
      J M Wu, D E Nitecki, S Biancalana and R I Feldman
      Molecular Pharmacology November 1996, 50 (5) 1355-1363;

  10. Bilodeau, L

    1. Membrane-delimited G protein-mediated coupling between V1a vasopressin receptor and dihydropyridine binding sites in rat glomerulosa cells.
      E Grazzini, T Durroux, M D Payet, L Bilodeau, N Gallo-Payet and G Guillon
      Molecular Pharmacology November 1996, 50 (5) 1273-1283;

  11. Birnbaumer, L

    1. Subunit composition is a major determinant in high affinity binding of a Ca2+ channel blocker.
      H Suh-Kim, X Wei and L Birnbaumer
      Molecular Pharmacology November 1996, 50 (5) 1330-1337;

  12. Blanchet, P J

    1. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
      M Morissette, M Goulet, F Calon, P Falardeau, P J Blanchet, P J Bédard and T Di Paolo
      Molecular Pharmacology November 1996, 50 (5) 1073-1079;

  13. Blaustein, M P

    1. Three new toxins from the scorpion Pandinus imperator selectively block certain voltage-gated K+ channels.
      R S Rogowski, J H Collins, T J O'Neill, T A Gustafson, T R Werkman, M A Rogawski, T C Tenenholz, D J Weber and M P Blaustein
      Molecular Pharmacology November 1996, 50 (5) 1167-1177;

  14. Bocos, C

    1. Rat 17 beta-hydroxysteroid dehydrogenase type IV is a novel peroxisome proliferator-inducible gene.
      J C Corton, C Bocos, E S Moreno, A Merritt, D S Marsman, P J Sausen, R C Cattley and J A Gustafsson
      Molecular Pharmacology November 1996, 50 (5) 1157-1166;

  15. Borkow, G

    1. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
      D Arion, R S Fletcher, G Borkow, M J Camarasa, J Balzarini, G I Dmitrienko and M A Parniak
      Molecular Pharmacology November 1996, 50 (5) 1057-1064;

  16. Boyer, J L

    1. Identification of competitive antagonists of the P2Y1 receptor.
      J L Boyer, T Romero-Avila, J B Schachter and T K Harden
      Molecular Pharmacology November 1996, 50 (5) 1323-1329;

  17. Boyle, J E

    1. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.
      D C Zeldin, J Foley, J Ma, J E Boyle, J M Pascual, C R Moomaw, K B Tomer, C Steenbergen and S Wu
      Molecular Pharmacology November 1996, 50 (5) 1111-1117;

  18. Bullock, A J

    1. Enantiomers of myo-inositol-1,3,4-trisphosphate and myo-inositol-1,4,6 -trisphosphate: stereospecific recognition by cerebellar and platelet myo-inositol-1,4,5-trisphosphate receptors.
      C T Murphy, A J Bullock, C J Lindley, S J Mills, A M Riley, B V Potter and J Westwick
      Molecular Pharmacology November 1996, 50 (5) 1223-1230;

C

  1. Cahard, D

    1. Antiretrovirus specificity and intracellular metabolism of 2',3' -didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324.
      J Balzarini, H Egberink, K Hartmann, D Cahard, T Vahlenkamp, H Thormar, E De Clercq and C McGuigan
      Molecular Pharmacology November 1996, 50 (5) 1207-1213;

  2. Calon, F

    1. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
      M Morissette, M Goulet, F Calon, P Falardeau, P J Blanchet, P J Bédard and T Di Paolo
      Molecular Pharmacology November 1996, 50 (5) 1073-1079;

  3. Camarasa, M J

    1. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
      D Arion, R S Fletcher, G Borkow, M J Camarasa, J Balzarini, G I Dmitrienko and M A Parniak
      Molecular Pharmacology November 1996, 50 (5) 1057-1064;

  4. Carter, D B

    1. Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2.
      F Knoflach, D Benke, Y Wang, L Scheurer, H Lüddens, B J Hamilton, D B Carter, H Mohler and J A Benson
      Molecular Pharmacology November 1996, 50 (5) 1253-1261;

  5. Catterall, W A

    1. Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines.
      B D Johnson, G H Hockerman, T Scheuer and W A Catterall
      Molecular Pharmacology November 1996, 50 (5) 1388-1400;

  6. Cattley, R C

    1. Rat 17 beta-hydroxysteroid dehydrogenase type IV is a novel peroxisome proliferator-inducible gene.
      J C Corton, C Bocos, E S Moreno, A Merritt, D S Marsman, P J Sausen, R C Cattley and J A Gustafsson
      Molecular Pharmacology November 1996, 50 (5) 1157-1166;

  7. Cho, W

    1. Mutagenesis of residues adjacent to transmembrane prolines alters D1 dopamine receptor binding and signal transduction.
      W Cho, L P Taylor and H Akil
      Molecular Pharmacology November 1996, 50 (5) 1338-1345;

  8. Claire, D C

    1. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells.
      J W Lawrence, D C Claire, V Weissig and T C Rowe
      Molecular Pharmacology November 1996, 50 (5) 1178-1188;

  9. Collins, J H

    1. Three new toxins from the scorpion Pandinus imperator selectively block certain voltage-gated K+ channels.
      R S Rogowski, J H Collins, T J O'Neill, T A Gustafson, T R Werkman, M A Rogawski, T C Tenenholz, D J Weber and M P Blaustein
      Molecular Pharmacology November 1996, 50 (5) 1167-1177;

  10. Corton, J C

    1. Rat 17 beta-hydroxysteroid dehydrogenase type IV is a novel peroxisome proliferator-inducible gene.
      J C Corton, C Bocos, E S Moreno, A Merritt, D S Marsman, P J Sausen, R C Cattley and J A Gustafsson
      Molecular Pharmacology November 1996, 50 (5) 1157-1166;

  11. Cross, A J

    1. Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury.
      N Tindberg, H A Baldwin, A J Cross and M Ingelman-Sundberg
      Molecular Pharmacology November 1996, 50 (5) 1065-1072;

D

  1. De Clercq, E

    1. Antiretrovirus specificity and intracellular metabolism of 2',3' -didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324.
      J Balzarini, H Egberink, K Hartmann, D Cahard, T Vahlenkamp, H Thormar, E De Clercq and C McGuigan
      Molecular Pharmacology November 1996, 50 (5) 1207-1213;
    2. Evidence for distinction of the differentiation-inducing activities and cytostatic properties of 9-(2-phosphonylmethoxyethyl)adenine and a variety of differentiation-inducing agents in human erythroleukemia K562 cells.
      S Hatse, E De Clercq and J Balzarini
      Molecular Pharmacology November 1996, 50 (5) 1231-1242;

  2. De Meis, L

    1. Pharmacological differentiation between intracellular calcium pump isoforms.
      S Engelender and L De Meis
      Molecular Pharmacology November 1996, 50 (5) 1243-1252;

  3. Di Paolo, T

    1. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
      M Morissette, M Goulet, F Calon, P Falardeau, P J Blanchet, P J Bédard and T Di Paolo
      Molecular Pharmacology November 1996, 50 (5) 1073-1079;

  4. Dmitrienko, G I

    1. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
      D Arion, R S Fletcher, G Borkow, M J Camarasa, J Balzarini, G I Dmitrienko and M A Parniak
      Molecular Pharmacology November 1996, 50 (5) 1057-1064;

  5. Dougherty, D A

    1. Dose-response relations for unnatural amino acids at the agonist binding site of the nicotinic acetylcholine receptor: tests with novel side chains and with several agonists.
      P C Kearney, M W Nowak, W Zhong, S K Silverman, H A Lester and D A Dougherty
      Molecular Pharmacology November 1996, 50 (5) 1401-1412;

  6. Drewe, J A

    1. Pharmacology of the human gamma-aminobutyric acidA receptor alpha 4 subunit expressed in Xenopus laevis oocytes.
      E R Whittemore, W Yang, J A Drewe and R M Woodward
      Molecular Pharmacology November 1996, 50 (5) 1364-1375;

  7. Duman, R S

    1. Differential regulation of corticotropin-releasing factor1 receptor expression by stress and agonist treatments in brain and cultured cells.
      P A Iredale, R Terwilliger, K L Widnell, E J Nestler and R S Duman
      Molecular Pharmacology November 1996, 50 (5) 1103-1110;

  8. Durroux, T

    1. Membrane-delimited G protein-mediated coupling between V1a vasopressin receptor and dihydropyridine binding sites in rat glomerulosa cells.
      E Grazzini, T Durroux, M D Payet, L Bilodeau, N Gallo-Payet and G Guillon
      Molecular Pharmacology November 1996, 50 (5) 1273-1283;

E

  1. Egberink, H

    1. Antiretrovirus specificity and intracellular metabolism of 2',3' -didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324.
      J Balzarini, H Egberink, K Hartmann, D Cahard, T Vahlenkamp, H Thormar, E De Clercq and C McGuigan
      Molecular Pharmacology November 1996, 50 (5) 1207-1213;

  2. Engelender, S

    1. Pharmacological differentiation between intracellular calcium pump isoforms.
      S Engelender and L De Meis
      Molecular Pharmacology November 1996, 50 (5) 1243-1252;

  3. Esbenshade, T A

    1. Coupling efficiencies of human alpha 1-adrenergic receptor subtypes: titration of receptor density and responsiveness with inducible and repressible expression vectors.
      T L Theroux, T A Esbenshade, R D Peavy and K P Minneman
      Molecular Pharmacology November 1996, 50 (5) 1376-1387;

F

  1. Falardeau, P

    1. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
      M Morissette, M Goulet, F Calon, P Falardeau, P J Blanchet, P J Bédard and T Di Paolo
      Molecular Pharmacology November 1996, 50 (5) 1073-1079;

  2. Feldman, R I

    1. Bombesin-like peptide receptor subtypes promote mitogenesis, which requires persistent receptor signaling.
      R I Feldman, M F Bartholdi and J M Wu
      Molecular Pharmacology November 1996, 50 (5) 1346-1354;
    2. Discovery of high affinity bombesin receptor subtype 3 agonists.
      J M Wu, D E Nitecki, S Biancalana and R I Feldman
      Molecular Pharmacology November 1996, 50 (5) 1355-1363;

  3. Fletcher, R S

    1. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
      D Arion, R S Fletcher, G Borkow, M J Camarasa, J Balzarini, G I Dmitrienko and M A Parniak
      Molecular Pharmacology November 1996, 50 (5) 1057-1064;

  4. Foley, J

    1. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.
      D C Zeldin, J Foley, J Ma, J E Boyle, J M Pascual, C R Moomaw, K B Tomer, C Steenbergen and S Wu
      Molecular Pharmacology November 1996, 50 (5) 1111-1117;

G

  1. Gallo-Payet, N

    1. Membrane-delimited G protein-mediated coupling between V1a vasopressin receptor and dihydropyridine binding sites in rat glomerulosa cells.
      E Grazzini, T Durroux, M D Payet, L Bilodeau, N Gallo-Payet and G Guillon
      Molecular Pharmacology November 1996, 50 (5) 1273-1283;

  2. George, S R

    1. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
      Y Pak, A Kouvelas, M A Scheideler, J Rasmussen, B F O'Dowd and S R George
      Molecular Pharmacology November 1996, 50 (5) 1214-1222;

  3. Gimble, J M

    1. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
      J M Gimble, C E Robinson, X Wu, K A Kelly, B R Rodriguez, S A Kliewer, J M Lehmann and D C Morris
      Molecular Pharmacology November 1996, 50 (5) 1087-1094;

  4. Gong, L

    1. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system.
      J M Masserano, L Gong, H Kulaga, I Baker and R J Wyatt
      Molecular Pharmacology November 1996, 50 (5) 1309-1315;

  5. Goulet, M

    1. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
      M Morissette, M Goulet, F Calon, P Falardeau, P J Blanchet, P J Bédard and T Di Paolo
      Molecular Pharmacology November 1996, 50 (5) 1073-1079;

  6. Grazzini, E

    1. Membrane-delimited G protein-mediated coupling between V1a vasopressin receptor and dihydropyridine binding sites in rat glomerulosa cells.
      E Grazzini, T Durroux, M D Payet, L Bilodeau, N Gallo-Payet and G Guillon
      Molecular Pharmacology November 1996, 50 (5) 1273-1283;

  7. Guillon, G

    1. Membrane-delimited G protein-mediated coupling between V1a vasopressin receptor and dihydropyridine binding sites in rat glomerulosa cells.
      E Grazzini, T Durroux, M D Payet, L Bilodeau, N Gallo-Payet and G Guillon
      Molecular Pharmacology November 1996, 50 (5) 1273-1283;

  8. Gunthorpe, M J

    1. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels.
      A C Hargreaves, M J Gunthorpe, C W Taylor and S C Lummis
      Molecular Pharmacology November 1996, 50 (5) 1284-1294;

  9. Gustafson, T A

    1. Three new toxins from the scorpion Pandinus imperator selectively block certain voltage-gated K+ channels.
      R S Rogowski, J H Collins, T J O'Neill, T A Gustafson, T R Werkman, M A Rogawski, T C Tenenholz, D J Weber and M P Blaustein
      Molecular Pharmacology November 1996, 50 (5) 1167-1177;

  10. Gustafsson, J A

    1. Rat 17 beta-hydroxysteroid dehydrogenase type IV is a novel peroxisome proliferator-inducible gene.
      J C Corton, C Bocos, E S Moreno, A Merritt, D S Marsman, P J Sausen, R C Cattley and J A Gustafsson
      Molecular Pharmacology November 1996, 50 (5) 1157-1166;

H

  1. Hamilton, B J

    1. Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2.
      F Knoflach, D Benke, Y Wang, L Scheurer, H Lüddens, B J Hamilton, D B Carter, H Mohler and J A Benson
      Molecular Pharmacology November 1996, 50 (5) 1253-1261;

  2. Hannuniemi, R

    1. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.
      K S Selander, J Mönkkönen, E K Karhukorpi, P Härkönen, R Hannuniemi and H K Väänänen
      Molecular Pharmacology November 1996, 50 (5) 1127-1138;

  3. Harden, T K

    1. Identification of competitive antagonists of the P2Y1 receptor.
      J L Boyer, T Romero-Avila, J B Schachter and T K Harden
      Molecular Pharmacology November 1996, 50 (5) 1323-1329;

  4. Hargreaves, A C

    1. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels.
      A C Hargreaves, M J Gunthorpe, C W Taylor and S C Lummis
      Molecular Pharmacology November 1996, 50 (5) 1284-1294;

  5. Härkönen, P

    1. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.
      K S Selander, J Mönkkönen, E K Karhukorpi, P Härkönen, R Hannuniemi and H K Väänänen
      Molecular Pharmacology November 1996, 50 (5) 1127-1138;

  6. Hartmann, K

    1. Antiretrovirus specificity and intracellular metabolism of 2',3' -didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324.
      J Balzarini, H Egberink, K Hartmann, D Cahard, T Vahlenkamp, H Thormar, E De Clercq and C McGuigan
      Molecular Pharmacology November 1996, 50 (5) 1207-1213;

  7. Hatse, S

    1. Evidence for distinction of the differentiation-inducing activities and cytostatic properties of 9-(2-phosphonylmethoxyethyl)adenine and a variety of differentiation-inducing agents in human erythroleukemia K562 cells.
      S Hatse, E De Clercq and J Balzarini
      Molecular Pharmacology November 1996, 50 (5) 1231-1242;

  8. Hoare, S R

    1. Regulation of D2 dopamine receptors by amiloride and amiloride analogs.
      S R Hoare and P G Strange
      Molecular Pharmacology November 1996, 50 (5) 1295-1308;

  9. Hockerman, G H

    1. Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines.
      B D Johnson, G H Hockerman, T Scheuer and W A Catterall
      Molecular Pharmacology November 1996, 50 (5) 1388-1400;

  10. Howell, S B

    1. Isolation and characterization of a cisplatin-resistant strain of Schizosaccharomyces pombe.
      P Perego, G Jimenez and S B Howell
      Molecular Pharmacology November 1996, 50 (5) 1080-1086;

  11. Hwa, J

    1. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding.
      M M Zhao, J Hwa and D M Perez
      Molecular Pharmacology November 1996, 50 (5) 1118-1126;

I

  1. Ingelman-Sundberg, M

    1. Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury.
      N Tindberg, H A Baldwin, A J Cross and M Ingelman-Sundberg
      Molecular Pharmacology November 1996, 50 (5) 1065-1072;

  2. Iredale, P A

    1. Differential regulation of corticotropin-releasing factor1 receptor expression by stress and agonist treatments in brain and cultured cells.
      P A Iredale, R Terwilliger, K L Widnell, E J Nestler and R S Duman
      Molecular Pharmacology November 1996, 50 (5) 1103-1110;

J

  1. Jezequel, S

    1. Novel antagonists of the inhibitory glycine receptor derived from quinolinic acid compounds.
      V Schmieden, S Jezequel and H Betz
      Molecular Pharmacology November 1996, 50 (5) 1200-1206;

  2. Jimenez, G

    1. Isolation and characterization of a cisplatin-resistant strain of Schizosaccharomyces pombe.
      P Perego, G Jimenez and S B Howell
      Molecular Pharmacology November 1996, 50 (5) 1080-1086;

  3. Johnson, B D

    1. Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines.
      B D Johnson, G H Hockerman, T Scheuer and W A Catterall
      Molecular Pharmacology November 1996, 50 (5) 1388-1400;

K

  1. Kan, H

    1. Involvement of mitogen-activated protein kinase and translocation of cytosolic phospholipase A2 to the nuclear envelope in acetylcholine-induced prostacyclin synthesis in rabbit coronary endothelial cells.
      H Kan, Y Ruan and K U Malik
      Molecular Pharmacology November 1996, 50 (5) 1139-1147;

  2. Karhukorpi, E K

    1. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.
      K S Selander, J Mönkkönen, E K Karhukorpi, P Härkönen, R Hannuniemi and H K Väänänen
      Molecular Pharmacology November 1996, 50 (5) 1127-1138;

  3. Katao, Y

    1. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
      M Minami, T Nakagawa, T Seki, T Onogi, Y Aoki, Y Katao, S Katsumata and M Satoh
      Molecular Pharmacology November 1996, 50 (5) 1413-1422;

  4. Katsumata, S

    1. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
      M Minami, T Nakagawa, T Seki, T Onogi, Y Aoki, Y Katao, S Katsumata and M Satoh
      Molecular Pharmacology November 1996, 50 (5) 1413-1422;

  5. Kearney, P C

    1. Dose-response relations for unnatural amino acids at the agonist binding site of the nicotinic acetylcholine receptor: tests with novel side chains and with several agonists.
      P C Kearney, M W Nowak, W Zhong, S K Silverman, H A Lester and D A Dougherty
      Molecular Pharmacology November 1996, 50 (5) 1401-1412;

  6. Kelly, K A

    1. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
      J M Gimble, C E Robinson, X Wu, K A Kelly, B R Rodriguez, S A Kliewer, J M Lehmann and D C Morris
      Molecular Pharmacology November 1996, 50 (5) 1087-1094;

  7. Kliewer, S A

    1. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
      J M Gimble, C E Robinson, X Wu, K A Kelly, B R Rodriguez, S A Kliewer, J M Lehmann and D C Morris
      Molecular Pharmacology November 1996, 50 (5) 1087-1094;

  8. Knoflach, F

    1. Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2.
      F Knoflach, D Benke, Y Wang, L Scheurer, H Lüddens, B J Hamilton, D B Carter, H Mohler and J A Benson
      Molecular Pharmacology November 1996, 50 (5) 1253-1261;

  9. Kouvelas, A

    1. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
      Y Pak, A Kouvelas, M A Scheideler, J Rasmussen, B F O'Dowd and S R George
      Molecular Pharmacology November 1996, 50 (5) 1214-1222;

  10. Krause, J E

    1. The neurokinin-1 receptor antagonist LY306,740 blocks nociception-induced increases in dorsal horn neurokinin-1 receptor gene expression.
      K E McCarson and J E Krause
      Molecular Pharmacology November 1996, 50 (5) 1189-1199;

  11. Kulaga, H

    1. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system.
      J M Masserano, L Gong, H Kulaga, I Baker and R J Wyatt
      Molecular Pharmacology November 1996, 50 (5) 1309-1315;

L

  1. Lawrence, J W

    1. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells.
      J W Lawrence, D C Claire, V Weissig and T C Rowe
      Molecular Pharmacology November 1996, 50 (5) 1178-1188;

  2. Lehmann, J M

    1. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
      J M Gimble, C E Robinson, X Wu, K A Kelly, B R Rodriguez, S A Kliewer, J M Lehmann and D C Morris
      Molecular Pharmacology November 1996, 50 (5) 1087-1094;

  3. Lester, H A

    1. Dose-response relations for unnatural amino acids at the agonist binding site of the nicotinic acetylcholine receptor: tests with novel side chains and with several agonists.
      P C Kearney, M W Nowak, W Zhong, S K Silverman, H A Lester and D A Dougherty
      Molecular Pharmacology November 1996, 50 (5) 1401-1412;

  4. Lindley, C J

    1. Enantiomers of myo-inositol-1,3,4-trisphosphate and myo-inositol-1,4,6 -trisphosphate: stereospecific recognition by cerebellar and platelet myo-inositol-1,4,5-trisphosphate receptors.
      C T Murphy, A J Bullock, C J Lindley, S J Mills, A M Riley, B V Potter and J Westwick
      Molecular Pharmacology November 1996, 50 (5) 1223-1230;

  5. Lüddens, H

    1. Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2.
      F Knoflach, D Benke, Y Wang, L Scheurer, H Lüddens, B J Hamilton, D B Carter, H Mohler and J A Benson
      Molecular Pharmacology November 1996, 50 (5) 1253-1261;

  6. Lummis, S C

    1. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels.
      A C Hargreaves, M J Gunthorpe, C W Taylor and S C Lummis
      Molecular Pharmacology November 1996, 50 (5) 1284-1294;

M

  1. Ma, J

    1. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.
      D C Zeldin, J Foley, J Ma, J E Boyle, J M Pascual, C R Moomaw, K B Tomer, C Steenbergen and S Wu
      Molecular Pharmacology November 1996, 50 (5) 1111-1117;

  2. Malik, K U

    1. Involvement of mitogen-activated protein kinase and translocation of cytosolic phospholipase A2 to the nuclear envelope in acetylcholine-induced prostacyclin synthesis in rabbit coronary endothelial cells.
      H Kan, Y Ruan and K U Malik
      Molecular Pharmacology November 1996, 50 (5) 1139-1147;

  3. Marsman, D S

    1. Rat 17 beta-hydroxysteroid dehydrogenase type IV is a novel peroxisome proliferator-inducible gene.
      J C Corton, C Bocos, E S Moreno, A Merritt, D S Marsman, P J Sausen, R C Cattley and J A Gustafsson
      Molecular Pharmacology November 1996, 50 (5) 1157-1166;

  4. Masserano, J M

    1. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system.
      J M Masserano, L Gong, H Kulaga, I Baker and R J Wyatt
      Molecular Pharmacology November 1996, 50 (5) 1309-1315;

  5. McCarson, K E

    1. The neurokinin-1 receptor antagonist LY306,740 blocks nociception-induced increases in dorsal horn neurokinin-1 receptor gene expression.
      K E McCarson and J E Krause
      Molecular Pharmacology November 1996, 50 (5) 1189-1199;

  6. McDonald, T F

    1. Cyclic AMP-independent inhibition of cardiac calcium current by forskolin.
      T Asai, S Pelzer and T F McDonald
      Molecular Pharmacology November 1996, 50 (5) 1262-1272;

  7. McGuigan, C

    1. Antiretrovirus specificity and intracellular metabolism of 2',3' -didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324.
      J Balzarini, H Egberink, K Hartmann, D Cahard, T Vahlenkamp, H Thormar, E De Clercq and C McGuigan
      Molecular Pharmacology November 1996, 50 (5) 1207-1213;

  8. Merritt, A

    1. Rat 17 beta-hydroxysteroid dehydrogenase type IV is a novel peroxisome proliferator-inducible gene.
      J C Corton, C Bocos, E S Moreno, A Merritt, D S Marsman, P J Sausen, R C Cattley and J A Gustafsson
      Molecular Pharmacology November 1996, 50 (5) 1157-1166;

  9. Mills, S J

    1. Enantiomers of myo-inositol-1,3,4-trisphosphate and myo-inositol-1,4,6 -trisphosphate: stereospecific recognition by cerebellar and platelet myo-inositol-1,4,5-trisphosphate receptors.
      C T Murphy, A J Bullock, C J Lindley, S J Mills, A M Riley, B V Potter and J Westwick
      Molecular Pharmacology November 1996, 50 (5) 1223-1230;

  10. Minami, M

    1. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
      M Minami, T Nakagawa, T Seki, T Onogi, Y Aoki, Y Katao, S Katsumata and M Satoh
      Molecular Pharmacology November 1996, 50 (5) 1413-1422;

  11. Minneman, K P

    1. Coupling efficiencies of human alpha 1-adrenergic receptor subtypes: titration of receptor density and responsiveness with inducible and repressible expression vectors.
      T L Theroux, T A Esbenshade, R D Peavy and K P Minneman
      Molecular Pharmacology November 1996, 50 (5) 1376-1387;

  12. Mohler, H

    1. Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2.
      F Knoflach, D Benke, Y Wang, L Scheurer, H Lüddens, B J Hamilton, D B Carter, H Mohler and J A Benson
      Molecular Pharmacology November 1996, 50 (5) 1253-1261;

  13. Mönkkönen, J

    1. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.
      K S Selander, J Mönkkönen, E K Karhukorpi, P Härkönen, R Hannuniemi and H K Väänänen
      Molecular Pharmacology November 1996, 50 (5) 1127-1138;

  14. Moomaw, C R

    1. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.
      D C Zeldin, J Foley, J Ma, J E Boyle, J M Pascual, C R Moomaw, K B Tomer, C Steenbergen and S Wu
      Molecular Pharmacology November 1996, 50 (5) 1111-1117;

  15. Moreno, E S

    1. Rat 17 beta-hydroxysteroid dehydrogenase type IV is a novel peroxisome proliferator-inducible gene.
      J C Corton, C Bocos, E S Moreno, A Merritt, D S Marsman, P J Sausen, R C Cattley and J A Gustafsson
      Molecular Pharmacology November 1996, 50 (5) 1157-1166;

  16. Morissette, M

    1. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
      M Morissette, M Goulet, F Calon, P Falardeau, P J Blanchet, P J Bédard and T Di Paolo
      Molecular Pharmacology November 1996, 50 (5) 1073-1079;

  17. Morris, D C

    1. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
      J M Gimble, C E Robinson, X Wu, K A Kelly, B R Rodriguez, S A Kliewer, J M Lehmann and D C Morris
      Molecular Pharmacology November 1996, 50 (5) 1087-1094;

  18. Murphy, C T

    1. Enantiomers of myo-inositol-1,3,4-trisphosphate and myo-inositol-1,4,6 -trisphosphate: stereospecific recognition by cerebellar and platelet myo-inositol-1,4,5-trisphosphate receptors.
      C T Murphy, A J Bullock, C J Lindley, S J Mills, A M Riley, B V Potter and J Westwick
      Molecular Pharmacology November 1996, 50 (5) 1223-1230;

N

  1. Nakagawa, T

    1. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
      M Minami, T Nakagawa, T Seki, T Onogi, Y Aoki, Y Katao, S Katsumata and M Satoh
      Molecular Pharmacology November 1996, 50 (5) 1413-1422;

  2. Nestler, E J

    1. Differential regulation of corticotropin-releasing factor1 receptor expression by stress and agonist treatments in brain and cultured cells.
      P A Iredale, R Terwilliger, K L Widnell, E J Nestler and R S Duman
      Molecular Pharmacology November 1996, 50 (5) 1103-1110;

  3. Nitecki, D E

    1. Discovery of high affinity bombesin receptor subtype 3 agonists.
      J M Wu, D E Nitecki, S Biancalana and R I Feldman
      Molecular Pharmacology November 1996, 50 (5) 1355-1363;

  4. Nitiss, J L

    1. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
      J L Nitiss and J C Wang
      Molecular Pharmacology November 1996, 50 (5) 1095-1102;

  5. Nowak, M W

    1. Dose-response relations for unnatural amino acids at the agonist binding site of the nicotinic acetylcholine receptor: tests with novel side chains and with several agonists.
      P C Kearney, M W Nowak, W Zhong, S K Silverman, H A Lester and D A Dougherty
      Molecular Pharmacology November 1996, 50 (5) 1401-1412;

O

  1. O'Dowd, B F

    1. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
      Y Pak, A Kouvelas, M A Scheideler, J Rasmussen, B F O'Dowd and S R George
      Molecular Pharmacology November 1996, 50 (5) 1214-1222;

  2. O'Neill, T J

    1. Three new toxins from the scorpion Pandinus imperator selectively block certain voltage-gated K+ channels.
      R S Rogowski, J H Collins, T J O'Neill, T A Gustafson, T R Werkman, M A Rogawski, T C Tenenholz, D J Weber and M P Blaustein
      Molecular Pharmacology November 1996, 50 (5) 1167-1177;

  3. Onogi, T

    1. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
      M Minami, T Nakagawa, T Seki, T Onogi, Y Aoki, Y Katao, S Katsumata and M Satoh
      Molecular Pharmacology November 1996, 50 (5) 1413-1422;

P

  1. Pak, Y

    1. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
      Y Pak, A Kouvelas, M A Scheideler, J Rasmussen, B F O'Dowd and S R George
      Molecular Pharmacology November 1996, 50 (5) 1214-1222;

  2. Pampori, N A

    1. Feminization of hepatic cytochrome P450s by nominal levels of growth hormone in the feminine plasma profile.
      N A Pampori and B H Shapiro
      Molecular Pharmacology November 1996, 50 (5) 1148-1156;

  3. Parniak, M A

    1. Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1", 2"-oxathiole-2",2"-dioxide] (TSAO).
      D Arion, R S Fletcher, G Borkow, M J Camarasa, J Balzarini, G I Dmitrienko and M A Parniak
      Molecular Pharmacology November 1996, 50 (5) 1057-1064;

  4. Pascual, J M

    1. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.
      D C Zeldin, J Foley, J Ma, J E Boyle, J M Pascual, C R Moomaw, K B Tomer, C Steenbergen and S Wu
      Molecular Pharmacology November 1996, 50 (5) 1111-1117;

  5. Payet, M D

    1. Membrane-delimited G protein-mediated coupling between V1a vasopressin receptor and dihydropyridine binding sites in rat glomerulosa cells.
      E Grazzini, T Durroux, M D Payet, L Bilodeau, N Gallo-Payet and G Guillon
      Molecular Pharmacology November 1996, 50 (5) 1273-1283;

  6. Peavy, R D

    1. Coupling efficiencies of human alpha 1-adrenergic receptor subtypes: titration of receptor density and responsiveness with inducible and repressible expression vectors.
      T L Theroux, T A Esbenshade, R D Peavy and K P Minneman
      Molecular Pharmacology November 1996, 50 (5) 1376-1387;

  7. Pelzer, S

    1. Cyclic AMP-independent inhibition of cardiac calcium current by forskolin.
      T Asai, S Pelzer and T F McDonald
      Molecular Pharmacology November 1996, 50 (5) 1262-1272;

  8. Perego, P

    1. Isolation and characterization of a cisplatin-resistant strain of Schizosaccharomyces pombe.
      P Perego, G Jimenez and S B Howell
      Molecular Pharmacology November 1996, 50 (5) 1080-1086;

  9. Perez, D M

    1. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding.
      M M Zhao, J Hwa and D M Perez
      Molecular Pharmacology November 1996, 50 (5) 1118-1126;

  10. Potter, B V

    1. Enantiomers of myo-inositol-1,3,4-trisphosphate and myo-inositol-1,4,6 -trisphosphate: stereospecific recognition by cerebellar and platelet myo-inositol-1,4,5-trisphosphate receptors.
      C T Murphy, A J Bullock, C J Lindley, S J Mills, A M Riley, B V Potter and J Westwick
      Molecular Pharmacology November 1996, 50 (5) 1223-1230;

R

  1. Rasmussen, J

    1. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
      Y Pak, A Kouvelas, M A Scheideler, J Rasmussen, B F O'Dowd and S R George
      Molecular Pharmacology November 1996, 50 (5) 1214-1222;

  2. Riley, A M

    1. Enantiomers of myo-inositol-1,3,4-trisphosphate and myo-inositol-1,4,6 -trisphosphate: stereospecific recognition by cerebellar and platelet myo-inositol-1,4,5-trisphosphate receptors.
      C T Murphy, A J Bullock, C J Lindley, S J Mills, A M Riley, B V Potter and J Westwick
      Molecular Pharmacology November 1996, 50 (5) 1223-1230;

  3. Robinson, C E

    1. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
      J M Gimble, C E Robinson, X Wu, K A Kelly, B R Rodriguez, S A Kliewer, J M Lehmann and D C Morris
      Molecular Pharmacology November 1996, 50 (5) 1087-1094;

  4. Rodriguez, B R

    1. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
      J M Gimble, C E Robinson, X Wu, K A Kelly, B R Rodriguez, S A Kliewer, J M Lehmann and D C Morris
      Molecular Pharmacology November 1996, 50 (5) 1087-1094;

  5. Rogawski, M A

    1. Three new toxins from the scorpion Pandinus imperator selectively block certain voltage-gated K+ channels.
      R S Rogowski, J H Collins, T J O'Neill, T A Gustafson, T R Werkman, M A Rogawski, T C Tenenholz, D J Weber and M P Blaustein
      Molecular Pharmacology November 1996, 50 (5) 1167-1177;

  6. Rogowski, R S

    1. Three new toxins from the scorpion Pandinus imperator selectively block certain voltage-gated K+ channels.
      R S Rogowski, J H Collins, T J O'Neill, T A Gustafson, T R Werkman, M A Rogawski, T C Tenenholz, D J Weber and M P Blaustein
      Molecular Pharmacology November 1996, 50 (5) 1167-1177;

  7. Romero-Avila, T

    1. Identification of competitive antagonists of the P2Y1 receptor.
      J L Boyer, T Romero-Avila, J B Schachter and T K Harden
      Molecular Pharmacology November 1996, 50 (5) 1323-1329;

  8. Rowe, T C

    1. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells.
      J W Lawrence, D C Claire, V Weissig and T C Rowe
      Molecular Pharmacology November 1996, 50 (5) 1178-1188;

  9. Ruan, Y

    1. Involvement of mitogen-activated protein kinase and translocation of cytosolic phospholipase A2 to the nuclear envelope in acetylcholine-induced prostacyclin synthesis in rabbit coronary endothelial cells.
      H Kan, Y Ruan and K U Malik
      Molecular Pharmacology November 1996, 50 (5) 1139-1147;

S

  1. Satoh, M

    1. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
      M Minami, T Nakagawa, T Seki, T Onogi, Y Aoki, Y Katao, S Katsumata and M Satoh
      Molecular Pharmacology November 1996, 50 (5) 1413-1422;

  2. Sausen, P J

    1. Rat 17 beta-hydroxysteroid dehydrogenase type IV is a novel peroxisome proliferator-inducible gene.
      J C Corton, C Bocos, E S Moreno, A Merritt, D S Marsman, P J Sausen, R C Cattley and J A Gustafsson
      Molecular Pharmacology November 1996, 50 (5) 1157-1166;

  3. Schachter, J B

    1. Identification of competitive antagonists of the P2Y1 receptor.
      J L Boyer, T Romero-Avila, J B Schachter and T K Harden
      Molecular Pharmacology November 1996, 50 (5) 1323-1329;

  4. Scheideler, M A

    1. Agonist-induced functional desensitization of the mu-opioid receptor is mediated by loss of membrane receptors rather than uncoupling from G protein.
      Y Pak, A Kouvelas, M A Scheideler, J Rasmussen, B F O'Dowd and S R George
      Molecular Pharmacology November 1996, 50 (5) 1214-1222;

  5. Scheuer, T

    1. Distinct effects of mutations in transmembrane segment IVS6 on block of L-type calcium channels by structurally similar phenylalkylamines.
      B D Johnson, G H Hockerman, T Scheuer and W A Catterall
      Molecular Pharmacology November 1996, 50 (5) 1388-1400;

  6. Scheurer, L

    1. Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2.
      F Knoflach, D Benke, Y Wang, L Scheurer, H Lüddens, B J Hamilton, D B Carter, H Mohler and J A Benson
      Molecular Pharmacology November 1996, 50 (5) 1253-1261;

  7. Schmieden, V

    1. Novel antagonists of the inhibitory glycine receptor derived from quinolinic acid compounds.
      V Schmieden, S Jezequel and H Betz
      Molecular Pharmacology November 1996, 50 (5) 1200-1206;

  8. Seki, T

    1. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
      M Minami, T Nakagawa, T Seki, T Onogi, Y Aoki, Y Katao, S Katsumata and M Satoh
      Molecular Pharmacology November 1996, 50 (5) 1413-1422;

  9. Selander, K S

    1. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.
      K S Selander, J Mönkkönen, E K Karhukorpi, P Härkönen, R Hannuniemi and H K Väänänen
      Molecular Pharmacology November 1996, 50 (5) 1127-1138;

  10. Shapiro, B H

    1. Feminization of hepatic cytochrome P450s by nominal levels of growth hormone in the feminine plasma profile.
      N A Pampori and B H Shapiro
      Molecular Pharmacology November 1996, 50 (5) 1148-1156;

  11. Silverman, S K

    1. Dose-response relations for unnatural amino acids at the agonist binding site of the nicotinic acetylcholine receptor: tests with novel side chains and with several agonists.
      P C Kearney, M W Nowak, W Zhong, S K Silverman, H A Lester and D A Dougherty
      Molecular Pharmacology November 1996, 50 (5) 1401-1412;

  12. Steenbergen, C

    1. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.
      D C Zeldin, J Foley, J Ma, J E Boyle, J M Pascual, C R Moomaw, K B Tomer, C Steenbergen and S Wu
      Molecular Pharmacology November 1996, 50 (5) 1111-1117;

  13. Strange, P G

    1. Regulation of D2 dopamine receptors by amiloride and amiloride analogs.
      S R Hoare and P G Strange
      Molecular Pharmacology November 1996, 50 (5) 1295-1308;

  14. Suh-Kim, H

    1. Subunit composition is a major determinant in high affinity binding of a Ca2+ channel blocker.
      H Suh-Kim, X Wei and L Birnbaumer
      Molecular Pharmacology November 1996, 50 (5) 1330-1337;

T

  1. Taylor, C W

    1. Direct inhibition of 5-hydroxytryptamine3 receptors by antagonists of L-type Ca2+ channels.
      A C Hargreaves, M J Gunthorpe, C W Taylor and S C Lummis
      Molecular Pharmacology November 1996, 50 (5) 1284-1294;

  2. Taylor, L P

    1. Mutagenesis of residues adjacent to transmembrane prolines alters D1 dopamine receptor binding and signal transduction.
      W Cho, L P Taylor and H Akil
      Molecular Pharmacology November 1996, 50 (5) 1338-1345;

  3. Tenenholz, T C

    1. Three new toxins from the scorpion Pandinus imperator selectively block certain voltage-gated K+ channels.
      R S Rogowski, J H Collins, T J O'Neill, T A Gustafson, T R Werkman, M A Rogawski, T C Tenenholz, D J Weber and M P Blaustein
      Molecular Pharmacology November 1996, 50 (5) 1167-1177;

  4. Terwilliger, R

    1. Differential regulation of corticotropin-releasing factor1 receptor expression by stress and agonist treatments in brain and cultured cells.
      P A Iredale, R Terwilliger, K L Widnell, E J Nestler and R S Duman
      Molecular Pharmacology November 1996, 50 (5) 1103-1110;

  5. Theroux, T L

    1. Coupling efficiencies of human alpha 1-adrenergic receptor subtypes: titration of receptor density and responsiveness with inducible and repressible expression vectors.
      T L Theroux, T A Esbenshade, R D Peavy and K P Minneman
      Molecular Pharmacology November 1996, 50 (5) 1376-1387;

  6. Thormar, H

    1. Antiretrovirus specificity and intracellular metabolism of 2',3' -didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324.
      J Balzarini, H Egberink, K Hartmann, D Cahard, T Vahlenkamp, H Thormar, E De Clercq and C McGuigan
      Molecular Pharmacology November 1996, 50 (5) 1207-1213;

  7. Tindberg, N

    1. Induction of cytochrome P450 2E1 expression in rat and gerbil astrocytes by inflammatory factors and ischemic injury.
      N Tindberg, H A Baldwin, A J Cross and M Ingelman-Sundberg
      Molecular Pharmacology November 1996, 50 (5) 1065-1072;

  8. Tomer, K B

    1. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.
      D C Zeldin, J Foley, J Ma, J E Boyle, J M Pascual, C R Moomaw, K B Tomer, C Steenbergen and S Wu
      Molecular Pharmacology November 1996, 50 (5) 1111-1117;

  9. Torres, G E

    1. 5-Hydroxytryptamine4 receptors reduce afterhyperpolarization in hippocampus by inhibiting calcium-induced calcium release.
      G E Torres, C L Arfken and R Andrade
      Molecular Pharmacology November 1996, 50 (5) 1316-1322;

V

  1. Väänänen, H K

    1. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages.
      K S Selander, J Mönkkönen, E K Karhukorpi, P Härkönen, R Hannuniemi and H K Väänänen
      Molecular Pharmacology November 1996, 50 (5) 1127-1138;

  2. Vahlenkamp, T

    1. Antiretrovirus specificity and intracellular metabolism of 2',3' -didehydro-2',3'-dideoxythymidine (stavudine) and its 5'-monophosphate triester prodrug So324.
      J Balzarini, H Egberink, K Hartmann, D Cahard, T Vahlenkamp, H Thormar, E De Clercq and C McGuigan
      Molecular Pharmacology November 1996, 50 (5) 1207-1213;

W

  1. Wang, J C

    1. Mechanisms of cell killing by drugs that trap covalent complexes between DNA topoisomerases and DNA.
      J L Nitiss and J C Wang
      Molecular Pharmacology November 1996, 50 (5) 1095-1102;

  2. Wang, Y

    1. Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2.
      F Knoflach, D Benke, Y Wang, L Scheurer, H Lüddens, B J Hamilton, D B Carter, H Mohler and J A Benson
      Molecular Pharmacology November 1996, 50 (5) 1253-1261;

  3. Weber, D J

    1. Three new toxins from the scorpion Pandinus imperator selectively block certain voltage-gated K+ channels.
      R S Rogowski, J H Collins, T J O'Neill, T A Gustafson, T R Werkman, M A Rogawski, T C Tenenholz, D J Weber and M P Blaustein
      Molecular Pharmacology November 1996, 50 (5) 1167-1177;

  4. Wei, X

    1. Subunit composition is a major determinant in high affinity binding of a Ca2+ channel blocker.
      H Suh-Kim, X Wei and L Birnbaumer
      Molecular Pharmacology November 1996, 50 (5) 1330-1337;

  5. Weissig, V

    1. Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells.
      J W Lawrence, D C Claire, V Weissig and T C Rowe
      Molecular Pharmacology November 1996, 50 (5) 1178-1188;

  6. Werkman, T R

    1. Three new toxins from the scorpion Pandinus imperator selectively block certain voltage-gated K+ channels.
      R S Rogowski, J H Collins, T J O'Neill, T A Gustafson, T R Werkman, M A Rogawski, T C Tenenholz, D J Weber and M P Blaustein
      Molecular Pharmacology November 1996, 50 (5) 1167-1177;

  7. Westwick, J

    1. Enantiomers of myo-inositol-1,3,4-trisphosphate and myo-inositol-1,4,6 -trisphosphate: stereospecific recognition by cerebellar and platelet myo-inositol-1,4,5-trisphosphate receptors.
      C T Murphy, A J Bullock, C J Lindley, S J Mills, A M Riley, B V Potter and J Westwick
      Molecular Pharmacology November 1996, 50 (5) 1223-1230;

  8. Whittemore, E R

    1. Pharmacology of the human gamma-aminobutyric acidA receptor alpha 4 subunit expressed in Xenopus laevis oocytes.
      E R Whittemore, W Yang, J A Drewe and R M Woodward
      Molecular Pharmacology November 1996, 50 (5) 1364-1375;

  9. Widnell, K L

    1. Differential regulation of corticotropin-releasing factor1 receptor expression by stress and agonist treatments in brain and cultured cells.
      P A Iredale, R Terwilliger, K L Widnell, E J Nestler and R S Duman
      Molecular Pharmacology November 1996, 50 (5) 1103-1110;

  10. Woodward, R M

    1. Pharmacology of the human gamma-aminobutyric acidA receptor alpha 4 subunit expressed in Xenopus laevis oocytes.
      E R Whittemore, W Yang, J A Drewe and R M Woodward
      Molecular Pharmacology November 1996, 50 (5) 1364-1375;

  11. Wu, J M

    1. Bombesin-like peptide receptor subtypes promote mitogenesis, which requires persistent receptor signaling.
      R I Feldman, M F Bartholdi and J M Wu
      Molecular Pharmacology November 1996, 50 (5) 1346-1354;
    2. Discovery of high affinity bombesin receptor subtype 3 agonists.
      J M Wu, D E Nitecki, S Biancalana and R I Feldman
      Molecular Pharmacology November 1996, 50 (5) 1355-1363;

  12. Wu, S

    1. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.
      D C Zeldin, J Foley, J Ma, J E Boyle, J M Pascual, C R Moomaw, K B Tomer, C Steenbergen and S Wu
      Molecular Pharmacology November 1996, 50 (5) 1111-1117;

  13. Wu, X

    1. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells.
      J M Gimble, C E Robinson, X Wu, K A Kelly, B R Rodriguez, S A Kliewer, J M Lehmann and D C Morris
      Molecular Pharmacology November 1996, 50 (5) 1087-1094;

  14. Wyatt, R J

    1. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system.
      J M Masserano, L Gong, H Kulaga, I Baker and R J Wyatt
      Molecular Pharmacology November 1996, 50 (5) 1309-1315;

Y

  1. Yang, W

    1. Pharmacology of the human gamma-aminobutyric acidA receptor alpha 4 subunit expressed in Xenopus laevis oocytes.
      E R Whittemore, W Yang, J A Drewe and R M Woodward
      Molecular Pharmacology November 1996, 50 (5) 1364-1375;

Z

  1. Zeldin, D C

    1. CYP2J subfamily P450s in the lung: expression, localization, and potential functional significance.
      D C Zeldin, J Foley, J Ma, J E Boyle, J M Pascual, C R Moomaw, K B Tomer, C Steenbergen and S Wu
      Molecular Pharmacology November 1996, 50 (5) 1111-1117;

  2. Zhao, M M

    1. Identification of critical extracellular loop residues involved in alpha 1-adrenergic receptor subtype-selective antagonist binding.
      M M Zhao, J Hwa and D M Perez
      Molecular Pharmacology November 1996, 50 (5) 1118-1126;

  3. Zhong, W

    1. Dose-response relations for unnatural amino acids at the agonist binding site of the nicotinic acetylcholine receptor: tests with novel side chains and with several agonists.
      P C Kearney, M W Nowak, W Zhong, S K Silverman, H A Lester and D A Dougherty
      Molecular Pharmacology November 1996, 50 (5) 1401-1412;
Back to top

In this issue

Advertisement